At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
The WATCHMAN FLX Delivery Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observe the Safety and Effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for Subjects With Non-valvular Atrial Fibrillation to Reduce the Risk of Stroke in Hong Kong Area
In Brief
An observational study evaluating The WATCHMAN FLX Delivery System for Non-valvular Atrial Fibrillation. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The primary objective of this study is to observe the safety and effectiveness of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device for subjects with non-valvular atrial fibrillation to reduce the risk of stroke in Hong Kong area.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-valvular Atrial Fibrillation
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartJun 2020
Primary CompletionJan 2022
Study CompletionMar 2023
TodayJul 2026
First PostedSep 20, 2019
Enrollment StartJun 19, 2020
Primary CompletionJan 24, 2022
Study CompletionMar 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.8 years ago
Interventions
The WATCHMAN FLX Delivery Systemdevice
WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium